EcoDrugPlus

Matrix Metallopeptidase 8

Ensembl ID : ENSBTAG00000046732
Gene Symbol: MMP8
7 Enzyme and pathways 5 Cross references
123 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSBTAG00000020676
Gene Symbol: MMP9
18 Enzyme and pathways 5 Cross references
228 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSBTAG00000015325
Gene Symbol: MTOR
21 Enzyme and pathways 5 Cross references
236 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSBTAG00000023731
Gene Symbol: MC1R
7 Enzyme and pathways 5 Cross references
166 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSBTAG00000004712
Gene Symbol: MC3R
7 Enzyme and pathways 5 Cross references
147 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSBTAG00000019676
Gene Symbol: MC4R
7 Enzyme and pathways 5 Cross references
230 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSBTAG00000046938
Gene Symbol: MTNR1A
6 Enzyme and pathways 5 Cross references
230 Possible Orthologues:

Melatonin Receptor 1b

Ensembl ID : ENSBTAG00000050009
Gene Symbol: MTNR1B
6 Enzyme and pathways 4 Cross references
118 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSBTAG00000002075
Gene Symbol: MME
9 Enzyme and pathways 5 Cross references
246 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSBTAG00000019944
Gene Symbol: METAP2
4 Enzyme and pathways 5 Cross references
242 Possible Orthologues:

Microtubule Associated Protein Tau

Ensembl ID : ENSBTAG00000017512
Gene Symbol: MAPT
5 Cross references
240 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSBTAG00000010312
Gene Symbol: MAPK1
125 Enzyme and pathways 5 Cross references
226 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).